DARE Daré Bioscience | $0.30 +7.1% | 4/17/2024 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | N/A | View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 4/17/2024 |
IMUX Immunic | $1.27 +3.3% | 4/5/2024 | Reiterated by | Brookline Capital Management | Analyst T. Bussian | Buy | $10.00 | Low | View details for Brookline Capital Management rating of Immunic (NASDAQ:IMUX) on 4/5/2024 |
FUSN Fusion Pharmaceuticals | $21.46 +0.3% | 3/19/2024 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | N/A | View details for Brookline Capital Management rating of Fusion Pharmaceuticals (NASDAQ:FUSN) on 3/19/2024 |
ATE Antibe Therapeutics | C$0.30
| 3/4/2024 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | N/A | View details for Brookline Capital Management rating of Antibe Therapeutics (TSE:ATE) on 3/4/2024 |
ATBPF Antibe Therapeutics | $0.22
| 3/4/2024 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 3/4/2024 |
ANVS Annovis Bio | $5.85 -19.6% | 2/28/2024 | Downgraded by | Brookline Capital Management | Analyst T. Bussian | Buy -> Hold | $9.00 | Low | View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 2/28/2024 |
|
OTLK Outlook Therapeutics | $8.93 -1.9% | 1/25/2024 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Hold -> Buy | $31.40 | Low | View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 1/25/2024 |
ONCT Oncternal Therapeutics | $8.27 -2.5% | 12/4/2023 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Hold -> Buy | $40.00 | Low | View details for Brookline Capital Management rating of Oncternal Therapeutics (NASDAQ:ONCT) on 12/4/2023 |
LNTH Lantheus | $66.95 -0.5% | 11/30/2023 | Initiated by | Brookline Capital Management | - | Buy | $100.00 | Low | View details for Brookline Capital Management rating of Lantheus (NASDAQ:LNTH) on 11/30/2023 |
ANVS Annovis Bio | $5.85 -19.6% | 11/10/2023 | Reiterated by | Brookline Capital Management | Analyst T. Bussian | Buy | $35.00 | Low | View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 11/10/2023 |
GNLX Genelux | $3.12 -1.6% | 10/30/2023 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Hold -> Buy | | Low | View details for Brookline Capital Management rating of Genelux (NASDAQ:GNLX) on 10/30/2023 |
EYEN Eyenovia | $0.80 +12.3% | 10/17/2023 | Initiated by | Brookline Capital Management | - | Buy | $8.00 | Low | View details for Brookline Capital Management rating of Eyenovia (NASDAQ:EYEN) on 10/17/2023 |
EDSA Edesa Biotech | $4.52 +3.4% | 10/12/2023 | Reiterated by | Brookline Capital Management | - | Buy -> Buy | $57.00 | Low | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/12/2023 |
OTLK Outlook Therapeutics | $8.93 -1.9% | 8/30/2023 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 8/30/2023 |
ATBPF Antibe Therapeutics | $0.22
| 8/14/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 8/14/2023 |
ONCT Oncternal Therapeutics | $8.27 -2.5% | 4/3/2023 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Oncternal Therapeutics (NASDAQ:ONCT) on 4/3/2023 |
ONCT Oncternal Therapeutics | $8.27 -2.5% | 3/9/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Oncternal Therapeutics (NASDAQ:ONCT) on 3/9/2023 |
DARE Daré Bioscience | $0.30 +7.1% | 2/14/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 2/14/2023 |
FUSN Fusion Pharmaceuticals | $21.46 +0.3% | 2/13/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Fusion Pharmaceuticals (NASDAQ:FUSN) on 2/13/2023 |
ECOR electroCore | $6.35 +11.4% | 1/12/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 1/12/2023 |
IMNN Imunon | $1.32 -2.9% | 11/14/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Imunon (NASDAQ:IMNN) on 11/14/2022 |
VXRT Vaxart | $0.69 -2.8% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 10/3/2022 |
OTLK Outlook Therapeutics | $8.93 -1.9% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 10/3/2022 |
MNPR Monopar Therapeutics | $0.68 +4.6% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 10/3/2022 |
LSTA Lisata Therapeutics | $2.77 +0.7% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Lisata Therapeutics (NASDAQ:LSTA) on 10/3/2022 |
IMNN Imunon | $1.32 -2.9% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Imunon (NASDAQ:IMNN) on 10/3/2022 |
EDSA Edesa Biotech | $4.52 +3.4% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/3/2022 |
ATE Antibe Therapeutics | C$0.30
| 8/15/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of Antibe Therapeutics (TSE:ATE) on 8/15/2022 |
ARCT Arcturus Therapeutics | $25.62 -3.8% | 8/10/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/10/2022 |
ATBPF Antibe Therapeutics | $0.22
| 6/30/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/30/2022 |
VERU Veru | $1.36 +8.8% | 5/18/2022 | Target Raised by | Brookline Capital Management | Analyst Kumaraguru Raja | Buy -> Buy | $29.00 -> $31.00 | Medium | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 5/18/2022 |
VRCA Verrica Pharmaceuticals | $6.92 -3.2% | 3/10/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Medium | View details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 3/10/2022 |
NTLA Intellia Therapeutics | $21.60 -1.7% | 3/7/2022 | Upgraded by | Brookline Capital Management | Analyst L. Cann | Hold -> Buy | $91.00 | High | View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 3/7/2022 |
CRSP CRISPR Therapeutics | $53.24 -2.9% | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst Leah Rush | Buy | $143.00 | High | View details for Brookline Capital Management rating of CRISPR Therapeutics (NASDAQ:CRSP) on 2/14/2022 |
NTLA Intellia Therapeutics | $21.60 -1.7% | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst Leah Rush | Buy | | Low | View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 2/14/2022 |
CRBU Caribou Biosciences | $3.69 -2.4% | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Medium | View details for Brookline Capital Management rating of Caribou Biosciences (NASDAQ:CRBU) on 2/14/2022 |
BCDA BioCardia | $0.38 +3.8% | 2/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 2/3/2022 |
FUSN Fusion Pharmaceuticals | $21.46 +0.3% | 2/2/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Medium | View details for Brookline Capital Management rating of Fusion Pharmaceuticals (NASDAQ:FUSN) on 2/2/2022 |
ICCM IceCure Medical | $1.18 -1.7% | 2/1/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of IceCure Medical (NASDAQ:ICCM) on 2/1/2022 |
DARE Daré Bioscience | $0.30 +7.1% | 1/19/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 1/19/2022 |
The “Next Bitcoin”? 10 CENT Crypto Set to Explode (Ad) The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%...
Is now exposing a 10-cent coin that just partnered with Amazon… Click For My #1 FREE Crypto for 2024 |
KYMR Kymera Therapeutics | $33.94 -2.1% | 10/13/2021 | Reiterated by | Brookline Capital Management | Analyst Leah Rush Cann | Buy | $80.00 | Medium | View details for Brookline Capital Management rating of Kymera Therapeutics (NASDAQ:KYMR) on 10/13/2021 |
FBRX Forte Biosciences | $0.74 +1.5% | 9/3/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Hold | | Low | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 9/3/2021 |
VERU Veru | $1.36 +8.8% | 8/27/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Medium | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/27/2021 |
SCYX SCYNEXIS | $1.73 -5.0% | 8/24/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/24/2021 |
CCCC C4 Therapeutics | $6.33 +0.2% | 6/25/2021 | Reiterated by | Brookline Capital Management | Analyst Leah Rush Cann | Buy | | High | View details for Brookline Capital Management rating of C4 Therapeutics (NASDAQ:CCCC) on 6/25/2021 |
ATE Antibe Therapeutics | C$0.30
| 6/3/2021 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of Antibe Therapeutics (TSE:ATE) on 6/3/2021 |
ATBPF Antibe Therapeutics | $0.22
| 6/3/2021 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Medium | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/3/2021 |
MNPR Monopar Therapeutics | $0.68 +4.6% | 5/25/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Medium | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 5/25/2021 |
BIOX Bioceres Crop Solutions | $11.98 -0.7% | 5/7/2021 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 5/7/2021 |
ONCT Oncternal Therapeutics | $8.27 -2.5% | 3/30/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | $320.00 | High | View details for Brookline Capital Management rating of Oncternal Therapeutics (NASDAQ:ONCT) on 3/30/2021 |
MRNA Moderna | $111.31 -0.3% | 2/26/2021 | Target Raised by | Brookline Capital Management | - | Buy | $180.00 -> $205.00 | Low | View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 2/26/2021 |
XFOR X4 Pharmaceuticals | $1.15 +5.5% | 12/17/2020 | Initiated by | Brookline Capital Management | Analyst L. Cann | Buy | $21.00 | High | View details for Brookline Capital Management rating of X4 Pharmaceuticals (NASDAQ:XFOR) on 12/17/2020 |
VERU Veru | $1.36 +8.8% | 12/14/2020 | Target Raised by | Brookline Capital Management | Analyst K. Raja | | $13.00 -> $17.00 | High | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 12/14/2020 |
SYRS Syros Pharmaceuticals | $5.32 -1.1% | 11/10/2020 | Initiated by | Brookline Capital Management | Analyst L. Cann | Buy | $190.00 | Low | View details for Brookline Capital Management rating of Syros Pharmaceuticals (NASDAQ:SYRS) on 11/10/2020 |
ECOR electroCore | $6.35 +11.4% | 10/23/2020 | Initiated by | Brookline Capital Management | Analyst S. Yanchus | Buy | $75.00 | Low | View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 10/23/2020 |
AWH Aspira Women's Health | $3.25 -2.4% | 10/14/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | High | View details for Brookline Capital Management rating of Aspira Women’s Health (NASDAQ:AWH) on 10/14/2020 |
MEIP MEI Pharma | $3.05 -1.0% | 10/12/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Medium | View details for Brookline Capital Management rating of MEI Pharma (NASDAQ:MEIP) on 10/12/2020 |
DMTK DermTech | $0.64 +7.6% | 9/11/2020 | Initiated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | High | View details for Brookline Capital Management rating of DermTech (NASDAQ:DMTK) on 9/11/2020 |
FBRX Forte Biosciences | $0.74 +1.5% | 8/28/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $90.00 | Low | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 8/28/2020 |
HUGE FSD Pharma | $0.41 -6.3% | 8/20/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of FSD Pharma (NASDAQ:HUGE) on 8/20/2020 |
HUGE FSD Pharma | $0.41 -6.3% | 8/20/2020 | Initiated by | Brookline Capital Management | - | Buy | $11.00 | N/A | View details for Brookline Capital Management rating of FSD Pharma (NASDAQ:HUGE) on 8/20/2020 |
KURA Kura Oncology | $19.98 -0.4% | 8/16/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Low | View details for Brookline Capital Management rating of Kura Oncology (NASDAQ:KURA) on 8/16/2020 |
VERU Veru | $1.36 +8.8% | 8/14/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/14/2020 |
ARCT Arcturus Therapeutics | $25.62 -3.8% | 8/11/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/11/2020 |
ATE Antibe Therapeutics | C$0.30
| 7/15/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | N/A | View details for Brookline Capital Management rating of Antibe Therapeutics (TSE:ATE) on 7/15/2020 |
MRNA Moderna | $111.31 -0.3% | 7/13/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | $95.00 | High | View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 7/13/2020 |
ASRT Assertio | $0.89 +5.3% | 6/3/2020 | Initiated by | Brookline Capital Management | - | Buy | $3.50 | Low | View details for Brookline Capital Management rating of Assertio (NASDAQ:ASRT) on 6/3/2020 |
OTLK Outlook Therapeutics | $8.93 -1.9% | 5/5/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 5/5/2020 |
DARE Daré Bioscience | $0.30 +7.1% | 4/28/2020 | Initiated by | Brookline Capital Management | Analyst S. Yanchus | Buy | $7.50 | High | View details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 4/28/2020 |
EDSA Edesa Biotech | $4.52 +3.4% | 3/30/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $70.00 | High | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 3/30/2020 |
CLPT ClearPoint Neuro | $5.37 +0.8% | 3/11/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | High | View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/11/2020 |
ARMP Armata Pharmaceuticals | $2.54 -2.3% | 3/13/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) on 3/13/2020 |
CLPT ClearPoint Neuro | $5.37 +0.8% | 3/12/2020 | Initiated by | Brookline Capital Management | - | Buy | $15.00 | N/A | View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/12/2020 |
MNPR Monopar Therapeutics | $0.68 +4.6% | 2/19/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $42.00 | High | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 2/19/2020 |
BIOX Bioceres Crop Solutions | $11.98 -0.7% | 2/4/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | N/A | View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 2/4/2020 |
BCDA BioCardia | $0.38 +3.8% | 11/26/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 11/26/2019 |
BCDA BioCardia | $0.38 +3.8% | 11/26/2019 | Initiated by | Brookline Capital Management | - | Buy | $22.00 | Low | View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 11/26/2019 |
MDNA Medicenna Therapeutics | C$2.25 -2.6% | 11/19/2019 | Reiterated by | Brookline Capital Management | - | Buy | C$4.00 | N/A | View details for Brookline Capital Management rating of Medicenna Therapeutics (TSE:MDNA) on 11/19/2019 |
SCYX SCYNEXIS | $1.73 -5.0% | 8/19/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/19/2019 |
VXRT Vaxart | $0.69 -2.8% | 8/15/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $6.00 | Low | View details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 8/15/2019 |
VERU Veru | $1.36 +8.8% | 7/29/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $12.00 | High | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 7/29/2019 |
CLRB Cellectar Biosciences | $3.12 +0.6% | 7/29/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $60.00 -> $60.00 | High | View details for Brookline Capital Management rating of Cellectar Biosciences (NASDAQ:CLRB) on 7/29/2019 |
ARCT Arcturus Therapeutics | $25.62 -3.8% | 7/24/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 7/24/2019 |
SCYX SCYNEXIS | $1.73 -5.0% | 1/4/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 1/4/2019 |
CLRB Cellectar Biosciences | $3.12 +0.6% | 11/20/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Cellectar Biosciences (NASDAQ:CLRB) on 11/20/2018 |
ARCT Arcturus Therapeutics | $25.62 -3.8% | 9/27/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 9/27/2018 |
TNXP Tonix Pharmaceuticals | $0.18 -2.0% | 7/27/2018 | Downgraded by | Brookline Capital Management | Analyst K. Raja | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 7/27/2018 |
TNXP Tonix Pharmaceuticals | $0.18 -2.0% | 5/1/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 5/1/2018 |